Policy | Boehringer Ingelheim UK
Policy
Boehringer Ingelheim has been transforming lives in healthcare since 1885. We create value through innovation by infusing long-term, sustainable thinking into our Human Pharma, Animal Health and biopharmaceutical contract manufacturing businesses.
We are committed to working with governments and healthcare systems to bring more health to patients and animals.
Policy Papers and Position Statements
Strengthening policy for CRM diseases: An action plan
No patient left behind: driving equity in cancer treatment access
Policy Paper - Healthy Returns - the role of the OBR in healthcare spending
Respiratory - Specialty White Paper ILD
Early diagnosis and Treatment in Chronic Kidney Disease: A Case for Change
NP-GB-107388 April 2026